Good Publicity26 Mar 2021 07:09
"Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Study demonstrates real-world effectiveness of ferric maltol
Clinical collaborators publish results from FRESH study in BMJ Open Gastroenterology
London, UK, 26 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes the recent publication in BMJ Open Gastroenterology, titled: "Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK."
The study details the positive results from a real-world study using ferric maltol to assess clinical characteristics and outcomes of patients with inflammatory bowel disease (IBD) receiving ferric maltol for iron-deficiency anaemia in the UK (FRESH Study).
The observational, multicentre study, retrospective cohort study included adults with IBD and iron-deficiency anaemia (IDA) and who also had serum ferritin levels below 30 µg/L or transferrin saturation below 20%, who received ferric maltol. The study concluded that ferric maltol increases haemoglobin and iron indices and is generally well tolerated in patients with IBD and IDA treated in clinical practice. These real-world data confirm the favourable benefit/risk balance findings from randomised control trials."